The RIO study will see whether immune-based therapy (called bNAbs) can be used to instead of HIV treatment (ART).
Two long-acting bNAbs or a placebo will be given by infusion and ART will be stopped.
The study is now open to people who started HIV treatment soon after they became HIV positive.
Although enrolment was due to start in Spring 2020, the study was delayed for a year because of COVID-19.
The study opened in June 2021 after participants have had COVID-19 vaccines. It will run for two years.
This short video below is about the RIO study.
RIO trial website
Please contact the study team if you are interested in joining RIO.
Pre-print journal article explaining the protocol for RIO in detail.